4ckd: Difference between revisions
No edit summary |
No edit summary |
||
Line 19: | Line 19: | ||
==See Also== | ==See Also== | ||
*[[Antibody 3D structures|Antibody 3D structures]] | *[[Antibody 3D structures|Antibody 3D structures]] | ||
*[[Galactosidase|Galactosidase]] | *[[Galactosidase 3D structures|Galactosidase 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 10:22, 23 October 2019
Model of complex between the E.coli enzyme beta-galactosidase and four single chain Fv antibody domains scFv13R4.Model of complex between the E.coli enzyme beta-galactosidase and four single chain Fv antibody domains scFv13R4.
Structural highlights
Publication Abstract from PubMedBinding of a single-chain Fv antibody to Escherichia coli beta-galactosidase (beta-gal) is known to stabilize the enzyme and activate several inactive point mutants, historically called antibody-mediated enzyme formation mutants. To understand the nature of this activation, we have determined by electron cryo-microscopy the structure of the complex between beta-gal and the antibody scFv13R4. Our structure localizes the scFv13R4 binding site to the crevice between domains 1 and 3 in each beta-gal subunit. The mutations that scFv13R4 counteracts are located between the antibody binding site and the active site of beta-gal, at one end of the TIM-barrel that forms domain 3 where the substrate lactose is hydrolyzed. The mode of binding suggests how scFv stabilizes both the active site of beta-gal and the tetrameric state. Molecular Mechanism of Antibody-Mediated Activation of beta-galactosidase.,Vinothkumar KR, McMullan G, Henderson R Structure. 2014 Mar 4. pii: S0969-2126(14)00039-2. doi:, 10.1016/j.str.2014.01.011. PMID:24613486[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|